Wegovy Pill at Six Months: What Real-World Data Shows

On January 5, 2026, Novo Nordisk made the Wegovy pill broadly available across 70,000+ U.S. pharmacies. It was the first oral GLP-1 approved for weight loss — a once-daily semaglutide 25mg tablet that promised equivalent efficacy to the weekly Wegovy injection. Six months later, the prescription count has surpassed 3 million. Here's what we've learned.

Trial Results vs Real World

The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks for patients who adhered to the full treatment protocol, and 13.6% in the intention-to-treat analysis (regardless of adherence). These results were described as "similar to injectable Wegovy 2.4mg" — which was the key selling point.

Real-world data at six months paints a more nuanced picture. Adherence to the strict dosing requirements — taking the pill first thing in the morning on an empty stomach, with no more than 4 ounces of water, then waiting at least 30 minutes before eating, drinking, or taking other medications — has proven challenging for many patients. The 30-minute fasting window is a genuine lifestyle friction point that the trial's controlled environment didn't fully capture.

Early real-world reports suggest weight loss outcomes are tracking closer to the 13.6% ITT result than the 16.6% per-protocol result, which is consistent with what adherence data would predict. Patients who maintain strict dosing discipline report results comparable to the injection. Those who are less consistent report more variable outcomes.

The Dosing Challenge

Wegovy pill's absorption depends on an empty stomach and the SNAC delivery technology that facilitates semaglutide uptake through the stomach lining. This is fundamentally different from the injectable, which provides predictable absorption via subcutaneous injection regardless of meal timing.

In contrast, Eli Lilly's Foundayo (orforglipron), approved in April 2026, can be taken any time of day without food or water restrictions. This is a meaningful differentiator and may explain early switching patterns among patients who found the Wegovy pill's restrictions difficult to maintain.

Pricing at Six Months

Current self-pay pricing for the Wegovy pill through Novo Nordisk's direct offers:

• 1.5mg starting dose: $149/month
• 4mg dose: $149–$199/month (introductory pricing through August 2026)
• 9mg and 25mg doses: $349/month

With commercial insurance and the Novo Nordisk savings card, copays can drop to $25 or less. Without insurance, the progression from $149 at starting dose to $349 at therapeutic dose is a significant price jump — and one that compounded semaglutide avoids entirely.

Who the Wegovy Pill Works Best For

The ideal Wegovy pill patient is someone who strongly prefers oral medication over injections, has a consistent morning routine that accommodates the 30-minute fasting requirement, has insurance that covers the medication with a low copay, and wants the reassurance of an FDA-approved product. For patients who don't meet all of these criteria, compounded semaglutide injections or Foundayo may be more practical options.